China Medical System Holdings (HKG:0867) said China's National Medical Products Administration approved its symptomatic obstructive hypertrophic cardiomyopathy (oHCM) drug, CMS-D003, for clinical trials, according to a Wednesday filing with the Hong Kong bourse.
CMS-D003 is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy by reducing excessive heart muscle contraction and improving heart function, the filing said.
The pharmaceutical's shares were up by almost 3% in recent trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。